# US 2012/0269837 A1 · SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269837 A1
- Document ID: US20120269837A1
- Status: Published application
- Kind: A1
- Application number: 13/492,237
- Filed: 2012-06-08
- Published: 2012-10-25
- Earliest claimed: 2003-11-26
- Inventors: Robert Huber; Peter Sondermann; Uwe Jacob; Kerstin Wendt; Chiara Cabrele; Luis Moroder
- Web page: https://patentgrep.com/patent/US20120269837A1

## CPC

- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb and FcγRIIa.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

An artificial peptide or polypeptide comprising a conformationally discriminating epitope (CDE) in its native conformation, wherein the CDE is structurally stabilized by circularization.

### Claim 55 (depends on 54)

The peptide or polypeptide claim 54, comprising artificial or glycosylated amino acids.

### Claim 56 (depends on 54)

The peptide or polypeptide claim 54, conjugated to a carrier molecule.

### Claim 57 (depends on 54)

The peptide or polypeptide of claim 54 comprising a CDE of an Fc receptor.

### Claim 58 (depends on 57)

The peptide or polypeptide of claim 57 comprising a CDE of FcγRIIb or FcγRIIa, the CDE comprising at least one residue which is unique to either FcγRIIb or FcγRIIa.

### Claim 59 (depends on 58)

The peptide or polypeptide of claim 58, wherein the CDE comprises amino acids 27 to 30, or amino acids 127 to 135 or amino acids 160 to 171 of FcγRIIb of SEQ ID NO: 2 or the corresponding amino acids of FcγRIIa of SEQ ID NO: 1, or the amino acid sequence of SEQ ID NO: 3.

### Claim 60 (depends on 57)

The peptide or polypeptide of claim 57 conjugated to FcγRIIb or FcγRIIa.

### Claim 61

A method of producing a peptide carrying a conformationally discriminating epitope (CDE) for the generation of antibodies specifically recognizing a protein of interest carrying such an epitope, comprising:
(a) providing a protein of interest,
(b) identifying a CDE on said protein,
(c) producing a peptide comprising the sequence of the CDE,
(d) structurally stabilizing the peptide by circularization so that the CDE is present in its native conformation.

### Claim 62 (depends on 61)

The method of claim 61, wherein the circularization of the peptide is achieved by generating cysteine bridges, or by bridging amino acid side chains that form a pseudopeptide.

### Claim 63 (depends on 61)

The method of claim 61, wherein the peptide is generated using amino acids carrying glycosylation moieties which are present on the protein of interest.

### Claim 64 (depends on 61)

The method of claim 61, further comprising:
(e) conjugating the peptide to a carrier molecule selected from haptens, polypeptides, peptides, and the protein of interest.

### Claim 65 (depends on 61)

A peptide or polypeptide comprising a CDE, obtained by the method of claim 61.

### Claim 66 (depends on 54)

A method comprising generating immunomodulatory substances specifically recognizing the CDE in its natural environment by providing the peptide or polypeptide of claim 54 as an immunogen in a environment suitable to generate the substance.

### Claim 67 (depends on 59)

A method comprising immunizing an animal or a transgenic animal expressing human FcγRIIa by administering an effective amount of the peptide or polypeptide of claim 59 to a subject in need thereof.

### Claim 68 (depends on 59)

A method comprising generating an antibody that can specifically recognize alleles of the FcγRIIa Arg/His polymorphism at position 131 or the FcγRIIa Val/Phe polymorphism at position 155 by providing an effective amount of the peptide or polypeptide of claim 59 in an environment effective to a subject to generate the antibody.

### Claim 69 (depends on 59)

A method of producing substances capable of discriminating between an antigen of interest and closely related antigens, comprising immunizing an animal with a peptide or polypeptide according to claim 59 or with a correctly folded peptide derived from FcγRIIb or FcγRIIa, or both, and isolating the resulting antibodies.

### Claim 70 (depends on 58)

A nucleic acid sequence encoding the peptide of claim 58 or an antibody or fragment or derivative thereof that specifically binds to human FcγRIIb or FcγRIIa in the natural environment of the Fc receptor.

### Claim 71 (depends on 70)

A nucleic acid vector comprising the nucleic acid sequence according to claim 70.

### Claim 72 (depends on 71)

A host cell transfected with a vector according to claim 71.

### Claim 73

A diagnostic kit for the detection of autoimmune diseases or cancer, comprising the antibody, fragment or derivative thereof that specifically binds to human FcγRIIb or FcγRIIa in the natural environment of the Fc receptor, or a recombinant peptide or polypeptide comprising a conformationally discriminating epitope (CDE) in its native conformation, wherein the CDE is structurally stabilized by circulization.

### Claim 74 (depends on 69)

The method of claim 69, further comprising generating recombinant immunomodulatory substances with antibodies.
